-
-
-
-
-
-
-
Daré Bioscience publishes Phase 1 sildenafil cream data in men
-
-
-
-
-
-
-
Daré Bioscience CEO Outlines Commercial Transformation, Pipeline Momentum and Potential Key Catalysts in Virtual Investor CEO Connect Segment
-
-
-
-
-
-
-
Daré Bioscience begins phase 2 trial of HPV infection treatment
-
-
-
-
-
-
-
Daré Bioscience Reports Full Year 2025 Financial Results and Provides Business Update
-
-
-
-
-
-
-
Daré Bioscience Announces FDA Clearance of IND for Phase 2 Clinical Study of DARE-HPV, a Potential Treatment for Persistent High-Risk HPV Infection, the Most Common Cause of Cervical Cancer
-
-
-
-
-
-
-
Daré Bioscience Receives $3.6 Million in Additional Grant Funding
-
-
-
-
-
-
-
Daré Bioscience Receives $4 Million Non-Dilutive Grant Installment; Total of $41.8M Received to Date of up to $49M Commitment Supporting Smart Drug Delivery Device for Contraception; Platform has Bro
-
1,233,818 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All


